Evolus (EOLS) Revenue & Revenue Breakdown
Evolus Revenue Highlights
Latest Revenue (Y)
$199.72M
Latest Revenue (Q)
$66.22M
Main Segment (Y)
Product
Main Geography (Y)
CANADA
Evolus Revenue by Period
Evolus Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $199.72M | 34.39% |
| 2022-12-31 | $148.62M | 49.10% |
| 2021-12-31 | $99.67M | 76.29% |
| 2020-12-31 | $56.54M | 61.89% |
| 2019-12-31 | $34.92M | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | - |
Evolus generated $199.72M in revenue during NA 2023, up 34.39% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Evolus Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $66.22M | 11.61% |
| 2024-03-31 | $59.33M | -2.73% |
| 2023-12-31 | $61.00M | 23.67% |
| 2023-09-30 | $49.32M | -0.05% |
| 2023-06-30 | $49.35M | 18.28% |
| 2023-03-31 | $41.72M | -4.41% |
| 2022-12-31 | $43.65M | 28.75% |
| 2022-09-30 | $33.90M | -8.78% |
| 2022-06-30 | $37.16M | 9.60% |
| 2022-03-31 | $33.91M | -2.16% |
| 2021-12-31 | $34.66M | 29.91% |
| 2021-09-30 | $26.68M | 2.22% |
| 2021-06-30 | $26.10M | 113.20% |
| 2021-03-31 | $12.24M | -40.51% |
| 2020-12-31 | $20.58M | 16.51% |
| 2020-09-30 | $17.66M | 126.25% |
| 2020-06-30 | $7.81M | -25.63% |
| 2020-03-31 | $10.50M | -46.03% |
| 2019-12-31 | $19.45M | 47.69% |
| 2019-09-30 | $13.17M | 469.75% |
| 2019-06-30 | $2.31M | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | - |
Evolus generated $66.22M in revenue during Q2 2024, up 11.61% compared to the previous quarter, and up 158.73% compared to the same period a year ago.
Evolus Revenue Breakdown
Evolus Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Product | $199.72M | $146.59M | $98.97M | $55.80M | $34.24M |
| Service | $2.36M | $2.02M | - | - | - |
Evolus's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (98.83%), and Service (1.17%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Dec 20 | Sep 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Service | $687.00K | $369.00K | $328.00K | $696.00K | $666.00K | $674.00K | $658.00K | $684.00K | - | - | - | - | - | - | - |
| Product | $66.22M | $58.96M | $60.67M | $49.32M | $48.68M | $41.05M | $42.99M | $33.22M | $37.16M | $33.23M | $34.66M | $26.68M | $25.40M | $20.58M | $16.92M |
Evolus's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Product (98.97%), and Service (1.03%).
Evolus Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 21 | Dec 20 |
|---|---|---|
| CANADA | $702.00K | $738.00K |
Evolus's latest annual revenue breakdown by geography, as of Dec 21: CANADA (100.00%).
Quarterly Revenue by Country
| Country | Mar 22 | Jun 21 | Sep 20 |
|---|---|---|---|
| CANADA | $682.00K | $702.00K | $738.00K |
Evolus's latest quarterly revenue breakdown by geography, as of Mar 22: CANADA (100.00%).
Evolus Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ALKS | Alkermes | $1.66B | $399.13M |
| PBH | Prestige Consumer Healthcare | $1.13B | $267.14M |
| PAHC | Phibro Animal Health | $977.89M | $263.22M |
| PCRX | Pacira BioSciences | $674.98M | $178.02M |
| SUPN | Supernus Pharmaceuticals | $607.52M | $168.32M |
| AMPH | Amphastar Pharmaceuticals | $593.24M | $182.39M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| ITCI | Intra-Cellular Therapies | $462.18M | $144.87M |
| PROC | Procaps Group | $409.92M | $118.41M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| EOLS | Evolus | $199.72M | $66.22M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
| SSIC | Silver Spike Investment | $11.72M | $2.76B |
| IXHL | Incannex Healthcare | - | - |
EOLS Revenue FAQ
What is Evolus’s yearly revenue?
Evolus's yearly revenue for 2023 was $199.72M, representing an increase of 34.39% compared to 2022. The company's yearly revenue for 2022 was $148.62M, representing an increase of 49.10% compared to 2021. EOLS's yearly revenue for 2021 was $99.67M, representing an increase of 76.29% compared to 2020.
What is Evolus’s quarterly revenue?
Evolus's quarterly revenue for Q2 2024 was $66.22M, a 11.61% increase from the previous quarter (Q1 2024), and a 34.20% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $59.33M, a -2.73% decrease from the previous quarter (Q4 2023), and a 42.21% increase year-over-year (Q1 2023). EOLS's quarterly revenue for Q4 2023 was $61M, a 23.67% increase from the previous quarter (Q3 2023), and a 39.76% increase year-over-year (Q4 2022).
What is Evolus’s revenue growth rate?
Evolus's revenue growth rate for the last 3 years (2021-2023) was 100.38%, and for the last 5 years (2019-2023) was 471.86%.
What are Evolus’s revenue streams?
Evolus's revenue streams in c 23 are Product, and Service. Product generated $199.72M in revenue, accounting 98.83% of the company's total revenue, up 36.24% year-over-year. Service generated $2.36M in revenue, accounting 1.17% of the company's total revenue, up 16.80% year-over-year.
What is Evolus’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Evolus was Product. This segment made a revenue of $199.72M, representing 98.83% of the company's total revenue.